Moreover, the 36-month beta value for KRON is 1.86. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KRON is 40.07M and currently, short sellers hold a 1.71% of that float. On May 10, 2024, KRON’s average trading volume was 416.74K shares.
KRON) stock’s latest price update
The stock of Kronos Bio Inc (NASDAQ: KRON) has decreased by -4.76 when compared to last closing price of 1.05. Despite this, the company has experienced a -1.96% fall in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-09 that Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.46 per share a year ago.
KRON’s Market Performance
Kronos Bio Inc (KRON) has experienced a -1.96% fall in stock performance for the past week, with a -11.50% drop in the past month, and a -5.66% drop in the past quarter. The volatility ratio for the week is 6.07%, and the volatility levels for the past 30 days are at 6.85% for KRON. The simple moving average for the last 20 days is -2.77% for KRON stock, with a simple moving average of -16.63% for the last 200 days.
Analysts’ Opinion of KRON
Many brokerage firms have already submitted their reports for KRON stocks, with Berenberg repeating the rating for KRON by listing it as a “Buy.” The predicted price for KRON in the upcoming period, according to Berenberg is $12 based on the research report published on September 14, 2022 of the previous year 2022.
H.C. Wainwright gave a rating of “Buy” to KRON, setting the target price at $35 in the report published on June 24th of the previous year.
KRON Trading at -11.02% from the 50-Day Moving Average
After a stumble in the market that brought KRON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.33% of loss for the given period.
Volatility was left at 6.85%, however, over the last 30 days, the volatility rate increased by 6.07%, as shares sank -10.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.40% lower at present.
During the last 5 trading sessions, KRON fell by -0.49%, which changed the moving average for the period of 200-days by -47.41% in comparison to the 20-day moving average, which settled at $1.0228. In addition, Kronos Bio Inc saw -20.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KRON starting from Frisbee Allison, who sale 12,105 shares at the price of $1.05 back on Feb 21 ’24. After this action, Frisbee Allison now owns 204,510 shares of Kronos Bio Inc, valued at $12,757 using the latest closing price.
Lin Charles Y, the SR VP, RESEARCH & DEVELOPMENT of Kronos Bio Inc, sale 12,036 shares at $1.05 during a trade that took place back on Feb 21 ’24, which means that Lin Charles Y is holding 234,603 shares at $12,685 based on the most recent closing price.
Stock Fundamentals for KRON
Current profitability levels for the company are sitting at:
- -19.38 for the present operating margin
- 0.47 for the gross margin
The net margin for Kronos Bio Inc stands at -17.47. The total capital return value is set at -0.65. Equity return is now at value -55.84, with -44.34 for asset returns.
Based on Kronos Bio Inc (KRON), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.78. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is 43.14.
Currently, EBITDA for the company is -114.01 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 3.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.24.
Conclusion
To wrap up, the performance of Kronos Bio Inc (KRON) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
